| Literature DB >> 29760794 |
Dongmei Wei1, Lin Wang2, Yuhan Chen3, Gang Yin1, Mei Jiang4, Rui Liu5, Hong Chen1, Xiyuan Sun4.
Abstract
Traditional Chinese medicine has been widely used in cancer treatment in China. Yangyin Fuzheng Decoction is a traditional Chinese compound medicine, composed of 12 traditional Chinese herbs. This study aimed to investigate anti-tumor activity and the underlying mechanisms of Yangyin Fuzheng Decoction combined with cisplatin in the treatment of lung cancer. We established lung cancer model in C57BL/6 mice injected with mouse Lewis lung cancer cells. Our results demonstrated that Yangyin Fuzheng Decoction treatment increased necrotic area in tumor tissue, and significantly enhanced the recruitment of inflammatory cells into the tumor. In addition, Yangyin Fuzheng Decoction treatment enhanced the anti-tumor efficacy of cisplatin and partially recovered mouse body weight loss caused by cisplatin treatment. Mechanistically, we found that Yangyin Fuzheng Decoction upregulated the expression of pro-apoptotic proteins p53 and Bax and suppressed the expression of anti-apoptotic protein Bcl-2. Combined treatment of Yangyin Fuzheng Decoction and cisplatin further increased p53 and Bax levels and suppressed Bcl-2 level. Taken together, these data suggest that Yangyin Fuzheng Decoction could synergistically enhance the apoptotic signaling in cancer cells during chemotherapy. In addition, it has health improving and immune response enhancing effects. Yangyin Fuzheng Decoction could be a promising adjunct agent for lung cancer chemotherapy.Entities:
Keywords: Chemotherapy; Chinese traditional medicine; Cisplatin; Lung cancer; Yangyin Fuzheng Decoction
Year: 2018 PMID: 29760794 PMCID: PMC5950585 DOI: 10.7150/jca.24525
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1Lewis lung cancer growth in each group. A. C57BL/6 mice with Lewis lung tumor were treated with saline control, Yangyin Fuzheng Decoction (YFD), cisplatin, or combination of YFD and cisplatin for 10 days. The growth of tumor was monitored by caliper measurement of tumor size twice a week for 3 weeks. *P < 0.05 Cisplatin + YFD vs. Control group. B. The tumor weight of each group on day 21 (n=6). *P < 0.05 vs. Control group. #P < 0.05 vs. YFD group or cisplatin group. C. Mice body weight of each group on day 21 (n=6). *P < 0.05 vs. Control group.
Figure 2Pathology of Lewis lung tumor tissues in each group. A. The morphology of the tumor tissues from mice treated with saline (control), YFD, cisplatin and YFD plus cisplatin on Day 21. B. Hematoxylin eosin staining of the tumor tissues. 100× and 400× magnification. Shown were representative images from 8 mice in each group.
Figure 3Immunohistochemical analysis of Bcl-2, Bax and p53 in Lewis lung tumor tissues in each group. A. Representative staining of Bcl-2 in tumor tissues from mice treated with saline (control), YFD, cisplatin and YFD plus cisplatin on Day 21. 400× magnification. B. Semi-quantitative analysis of Bcl-2 staining (n=6). *P < 0.05 vs. Control group. C. Representative staining of p53 in tumor tissues. 400× magnification. D. Semi-quantitative analysis of p53 staining (n=6). *P < 0.05 vs. Control group. E. Representative staining of Bax in tumor tissues. 400× magnification. F. Semi-quantitative analysis of Bax staining (n=6). *P < 0.05 vs. Control group.